FDA Clears Ezplaz — First Freeze‑Dried, Shelf‑Stable Plasma Approved in U.S.

On July 29, the U.S. Food and Drug Administration approved the nation's first freeze-dried plasma product, granting a biologics license to Vascular Solutions, a subsidiary of Teleflex, for Ezplaz Freeze Dried Plasma. The product is indicated for adult patients who require plasma transfusions when conventional plasma products are unavailable.

Ezplaz is designed to be stored at room temperature and can be rapidly reconstituted for transfusion, removing the need for frozen storage and time-consuming thawing. The product is packaged in a plastic bag rather than a glass bottle, simplifying transport and reducing the risk of breakage during shipment and handling.

Context and Need

The approval arrives amid a national blood supply shortage. The American Red Cross — one of the largest U.S. suppliers of blood products — has reported donations at a four-year summer low and said it currently holds under a one-day national supply of O positive blood, prompting limits on shipments to some hospitals.

Potential Impact

The FDA noted that a room-temperature, quickly reconstituted plasma product could expand access to life-saving transfusions in settings where conventional plasma is difficult to obtain: combat zones, disaster-response operations and rural areas with limited hospital infrastructure. Because Ezplaz is stable at ambient temperatures and easier to transport, it may shorten response times in emergencies.

Ezplaz is produced from a single unit of fresh frozen plasma collected at FDA‑licensed blood establishments. It will be available in Group AB and Group A low‑titer anti‑B blood types for emergency use before a patient's blood type is known.

Note: The authorization is limited to situations where other plasma products cannot be obtained. Clinicians should follow applicable guidelines and institutional protocols when using Ezplaz.